Varicella zoster virus (VZV) infection is a frequent complication following bone marrow transplantation (BMT). Involvement of the ophthalmic division of the trigeminal nerve, herpes zoster ophthalmicus (HZO), can result in significant and potentially vision-threatening ocular complications. We report the frequency and characteristics of HZO following BMT, including the timing of infection, treatment, ocular complications, and visual outcome. Between 1983 and 1997, 572 patients underwent BMT and seven children developed HZO at a median of 150 days following transplantation. All but one of the children had undergone allogeneic BMT. All of the children were treated with acyclovir after onset of the rash but none had received prophylactic therapy. All seven children developed ocular complications within the first 4 weeks following the onset of the dermatomal rash but none reported any symptoms during this period. Complications included keratitis in six, anterior uveitis in three and scleritis in one. Keratitis was an early complication developing within the first 4 weeks, while anterior uveitis and scleritis occurred later in the course of the disease. The high frequency of ocular complications and lack of symptoms in children with HZO following BMT suggests that early ophthalmologic evaluation is warranted in this group of patients. Prompt diagnosis and treatment of ocular complications is essential in the prevention of acute and long-term ocular sequelae in these children. Keywords: herpes zoster ophthalmicus; bone marrow transplantation; varicella zoster; keratitis; uveitis; scleritis Varicella zoster virus (VZV) infection is a relatively frequent complication following autologous and allogeneic BMT. [1] [2] [3] [4] [5] [6] The clinical course of zoster in these immunosuppressed patients tends to be more severe and prolonged due to the profound impairment in cellular immunity following transplantation. VZV infection may develop as a primary infection or more commonly, reactivation of latent infection typically producing dermatomal zoster. 6 In most series, the risk for infection appears to be highest during the 6-9 months following transplantation and up to 30% of patients who develop VZV following BMT will develop complications.
risk for infection appears to be highest during the 6-9 months following transplantation and up to 30% of patients who develop VZV following BMT will develop complications. [3] [4] [5] [6] Involvement of the ophthalmic division of the trigeminal nerve -herpes zoster ophthalmicus -can result in serious and potentially vision-threatening ocular complications. 7 In adults, up to 72% of patients will develop ocular complications. 8 However, because HZO is uncommon in the pediatric population there is little information on the nature of the disease in children. 9 The purpose of this study was to describe the frequency and characteristics of HZO in children following BMT.
Patients and methods
To identify all children developing HZO following BMT, a computerized search of the BMT database at St Jude Children's Research Hospital in Memphis, TN was performed. All patients with a diagnosis of varicella zoster involving the ophthalmic division of the trigeminal nerve following BMT were identified and each medical record was reviewed to confirm the diagnosis. Clinical data supporting the diagnosis of HZO were reviewed and in all cases infection was documented by the presence of a characteristic vesicular rash involving the distribution of the ophthalmic division of the trigeminal nerve. Laboratory confirmation of the diagnosis by culture, skin biopsy, or serial rise in antibody titers was obtained in some but not all patients. The medical records of all children with confirmed HZO were then reviewed in detail. Extracted data included age, gender, diagnosis, history of primary varicella, pre-transplant serology, BMT preparative regimen, type of transplant, GVHD prophylaxis, antiviral prophylaxis, antiviral therapy, GVHD therapy, ocular complications and therapy, and duration of follow-up.
Results
Between January 1983 and December 1997, 572 children underwent BMT. Of 572 BMT recipients, 41 (7.2%) developed varicella zoster and of these, seven (1.2%) had involvement of the ophthalmic division of the trigeminal nerve (HZO). Characteristics of the seven children are shown in Table 1 . Affected children included four females and three males with a median age of 12 years (range, 9- Ara-C = cytosine arabinoside; TBI = total body irradiation; ATG = anti-thymocyte globulin.
15 years). The median follow-up for this group of children was 4 years (range, 2-6 years). Three of the children had CML, three relapsed ALL, and one AML. Six of the seven (85.7%) received allogeneic BMT with preparative regimens that included cyclophosphamide, cytosine arabinoside and total body irradiation (12-14 Gy in 6 to 8 fractions over 3 to 4 days). The other child received an autologous transplant with preparative chemotherapy consisting of busulfan and cyclophosphamide. All of the children undergoing allogeneic transplants also received prophylaxis for GVHD including cyclosporine in five of six and combination prednisone and methotrexate in the other child. Three of the children developed grade I or II acute GVHD between 10 and 22 days following transplant. Treatment for acute GVHD consisted of the addition of methylprednisolone to the prophylactic therapy.
All of the children had a history of primary varicella preceding the diagnosis of leukemia except the youngest child in the study (patient 2). This patient developed primary varicella following the diagnosis of ALL. After relapse of the ALL, he was treated with 10.8 Gy of cranial irradiation and developed HZO 3 weeks later. He was treated with intravenous acyclovir for 2 weeks and then underwent allogeneic BMT. All of the vesicular lesions had crusted prior to transplantation. Patient 3 had a negative VZV titer prior to BMT despite a history of primary varicella 3 years before the diagnosis of leukemia. None of the patients in this group received acyclovir prophylactically before or following BMT.
The median time between BMT and onset of dermatomal rash was 150 days (range, 28 days to 44 months). However six patients (85.7%) developed HZO within 8 months following transplantation. Initial manifestations in all of the children consisted of pain and vesicular rash involving the ophthalmic division of the trigeminal nerve. All patients were treated with acyclovir 1500 mg/m 2 /day for a median of 12 days (range, 11-14 days). All of the children subsequently developed ocular complications within 4 weeks following onset of the rash. Patient two developed ocular complications during the first week while the remaining six children (85.7%) developed ocular findings between days 14 and 28 following onset of the rash. Table 2 summarizes the ophthalmic complications in the seven children. All of the complications were confined to the anterior segment of the right eye and none of the children had ocular symptoms at the time complications were noted. Corneal complications included stromal keratitis in six patients (85.7%), punctate epithelial keratitis in two (28.6%), and pseudodendrites in one (14.3%). Three of the patients with stromal keratitis eventually developed chronic keratitis with a median duration of 20 months (range, 14-25 months). Additional ocular findings included acute anterior uveitis in three patients and anterior scleritis in one patient. Uveitis developed in the three children after 3, 13 and 56 weeks following the onset of HZO. Only the patient who developed uveitis after 13 months noted symptoms consisting of photophobia prior to examination. Patient 3 complained of pain with eye movement 20 weeks after the onset of the dermatomal rash and was found to have anterior scleritis. At the time of last evaluation, the visual acuity in Table 2 Ocular complications in children with HZO (14) the affected eye was 20/20 or better in five children, 20/25 in one, and 20/30 in the remaining child. Visual acuity was decreased in the two children because of pre-existing cataract in patient 3 and chronic stromal keratitis in patient 5.
Ocular complications n (%)

Discussion
Varicella zoster virus is a common complication following bone marrow transplantation. Reactivation of latent infection involving the ophthalmic division of the trigeminal nerve can lead to serious and potentially vision-threatening complications. The onset of HZO is typically heralded by headache, malaise, fever, and chills and is usually followed by the development of neuralgic pain in the distribution of the ophthalmic division of the trigeminal nerve, although the pain may precede the prodromal symptoms in some cases. 10 Erythema and edema develops within the affected dermatome over several days followed by the onset of characteristic crops of grouped vesicles. Ocular complications of HZO can affect all regions of the eye and include extraocular muscle palsies, cicatricial changes of the eyelid, conjunctivitis, episcleritis, scleritis, keratitis, iridocyclitis, sectoral iris atrophy, glaucoma, optic neuritis, retinitis, and retinal vasculitis. 10 Anterior segment complications of HZO are common and include conjunctivitis, episcleritis, scleritis, keratitis, iridocyclitis, and glaucoma. Conjunctivitis is a frequent finding during the acute phase of the disease. Episcleritis or scleritis may also develop during the acute phase or months later. Patients with scleritis or severe episcleritis may require therapy with systemic nonsteroidal therapy to control their symptoms. 10 Keratitis occurs in approximately two-thirds of patients with HZO. [10] [11] [12] [13] Several forms of keratitis may occur as a result of active infection or an immune response. Punctate epithelial keratitis and pseudodendrites are probably the two most common forms of keratitis. These forms of keratitis occur during the acute stage of the disease and result from active viral infection. Both types of keratitis are self-limiting and clear within several days following onset. Anterior stromal keratitis typically develops between the second and third week of the disease and represents an immune response to viral antigen. Topical corticosteroid therapy is effective in treating this immunemediated keratitis. However, some patients will require chronic low-dose therapy to prevent recurrence.
Ocular complications developed in all of our patients within 4 weeks following the onset of the vesicular rash. All of the children were seen initially within 72 h of onset of the rash and only one child had ocular findings at the time of initial evaluation. This child (patient 2) had initially developed HZO several weeks prior to BMT and was noted to have stromal keratitis at the time of initial evaluation. The short interval between the development of HZO and BMT may have contributed to the earlier onset of ocular disease in this particular patient.
Follow-up examinations were performed 2-3 weeks following the initial evaluation and ocular complications were noted in the remainder of the children at this second evaluation. However, none of the complications that developed during this first 4 weeks were accompanied by ocular symptoms in any of the children. Anterior uveitis and scleritis occurred later in the course of the disease compared to the corneal complications. It is noteworthy that all of the ocular complications in this group of children affected only the anterior segment of the eye.
Earlier reports have described possible risk factors for the development of varicella zoster in children following BMT. 6, 14, 15 Underlying hematologic malignancy, use of radiation in the preparative regimen, allogeneic transplant, development of severe acute GVHD, age 10 years or greater, and VZV seropositivity prior to BMT have been identified as possible risk factors. Similar to the findings in these reports, all of our children had a diagnosis of leukemia and all but one of the children received TBI prior to allogeneic transplant. Additionally, all but one of the children were aged 10 or older. However, none of our patients had experienced severe acute GVHD.
Based upon our results, we believe that all children who develop HZO following BMT should undergo prompt evaluation by an ophthalmologist. A complete examination should be performed including slit-lamp and fundus examination. Although many patients will not have any ocular findings at the time of initial evaluation, a repeat examination should be performed during the next 2-3 weeks, or sooner if symptoms develop. Prompt diagnosis and treatment of ocular complications is essential in the prevention of acute and long-term ocular sequelae in these children.
